Rosuvastatin, a new statin, has been shown to possess a number of advantageous
pharmacological properties, including enhanced HMG‐CoA reductase binding …

Rosuvastatin (Crestor®, AstraZeneca) is a synthetic statin that represents an advance on the
pharmacologic and clinical properties of other agents in this class. Relative to other statins …

Rosuvastatin (Crestor®; licensed to AstraZeneca, Macclesfield, UK from Shionogi, Osaka,
Japan) is a new statin with pharmacologic characteristics that translate into selectivity of …

Rosuvastatin is a new HMG‐CoA reductase inhibitor with unique pharmacologic and
pharmacokinetic properties. It has additional HMG‐CoA reductase enzyme‐binding …

Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has
minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin) …

Rosuvastatin is a synthetic statin that represents an advance in the pharmacologic and
clinical properties of statins. Relative to other statins, rosuvastatin possesses a greater …

Abstract Rosuvastatin (Crestor®), an HMG-CoA reductase inhibitor (statin), has a favorable
pharmacologic profile, including its selective uptake by hepatic cells, hydrophilic nature, and …

Rosuvastatin (Crestor®, AstraZeneca) is a new synthetic statin that exhibits a number of
highly desirable pharmacologic characteristics. The drug has a high affinity for the active site …

Abstract▴ Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively …

Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique
pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration …